scholarly journals Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature

Cureus ◽  
2021 ◽  
Author(s):  
Mathew Chatham ◽  
Polly Niravath
2021 ◽  
Author(s):  
Michael Lehner ◽  
Jinesh S. Gheeya ◽  
Bilal A. Siddiqui ◽  
Sudhakar Tummala

Abstract Paraneoplastic cerebellar degeneration (PCD) is a rare set of neurological disorders arising from tumor-associated autoimmunity against antigens within the cerebellum. Anti-Purkinje cell cytoplasmic antibody 1 (PCA-1), or anti-Yo, is the most commonly linked antibody and is classically associated with breast and ovarian cancers. Here we report case series of PCA-1 associated PCD in patients with known breast or ovarian cancer diagnosis not receiving immunotherapy. These cases highlight recognizing PCA-1 paraneoplastic syndrome triggered by cytotoxic chemotherapy, surgery, tumor recurrence and associated with development of second cancer. Diagnosis of the syndrome requires neurological workup with lumbar puncture (LP) with cerebrospinal fluids (CSF) studies, serum and CSF paraneoplastic antibody panel, and neuroimaging. Inpatient admission for prompt workup and initiation of treatment is recommended. Treatment most commonly includes immunosuppression with corticosteroids, plasmapheresis, and/or intravenous immune globulin (IVIG); however, we postulate that other immune modulating treatments may warrant consideration. In established cancer patients developing this syndrome, workup and treatment of tumor recurrence or development of second malignancy is recommended. These cases highlight the need for early recognition of the syndrome in patients receiving non immune based chemotherapy, for prompt workup and treatment.


2020 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Ajay Gogia ◽  
Ilavarasi Vanidassane ◽  
Vinod Raina ◽  
Priya Tiwari

2021 ◽  
pp. 100826
Author(s):  
Michalis Liontos ◽  
Oraianthi Fiste ◽  
Danai Drakopoulou ◽  
Nikolaos Thomakos ◽  
Kalliroi Goula ◽  
...  

2019 ◽  
Vol 24 (38) ◽  
pp. 4534-4539 ◽  
Author(s):  
Eric Zimmermann ◽  
Fawzi Ameer ◽  
Berhane Worku ◽  
Dimitrios Avgerinos

Introduction: Proximal aorta interventions impose significant bleeding risk. Patients on concomitant anticoagulation regimens compound the risk of bleeding in any surgery, but especially cardiothoracic interventions. The employment of direct-acting oral anticoagulants (DOAC), namely those that target clotting factors II or X, has expanded at a precipitous rate over the last decade. The emergence of their reversal agents has followed slowly, leaving clinicians with management dilemmas in urgent surgery. We discuss current reversal strategies based on the available published data and our experience with proximal aortic surgery in patients taking DOACs. Literature Search: We performed a review of literature and present three cases from our experience to offer insight into management strategies that have been historically successful. A review of literature was conducted via PubMed with the following search string: (NOAC or DOAC or TSOAC) and (aorta or aortic or (Stanford and type and a)). Case Presentation: We present three case presentations that illustrate the importance of DOAC identification and offer management strategies in mitigating associated bleeding risks in urgent or emergent surgeries. Conclusion: Treatment teams should be aware of the technical limitations of identifying and reversing DOACs. In view of the tendency toward publishing positive outcomes, more scientific rigor is required in the area of emergency DOAC reversal strategies.


Sign in / Sign up

Export Citation Format

Share Document